The 3Ds in Virus-like Particle Based-vaccines: "Design, Delivery and Dynamics"

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2020 May 31

PMID 32472710

Citations 52

Authors

Mona O Mohsen

Gilles Augusto

Martin F Bachmann

Affiliations

Soon will be listed here.

Abstract

Vaccines need to be rationally designed in order be delivered to the immune system for maximizing induction of dynamic immune responses. Virus-like particles (VLPs) are ideal platforms for such 3D vaccines, as they allow the display of complex and native antigens in a highly repetitive form on their surface and can easily reach lymphoid organs in intact form for optimal activation of B and T cells. Adjusting size and zeta potential may allow investigators to further fine-tune delivery to lymphoid organs. An additional way to alter vaccine transfer to lymph nodes and spleen may be the formulation with micron-sized adjuvants that creates a local depot and results in a slow release of antigen and adjuvant. Ideally, the adjuvant in addition stimulates the innate immune system. The dynamics of the immune response may be further enhanced by inclusion of Toll-like receptor ligands, which many VLPs naturally package. Hence, considering the 3Ds in vaccine development may allow for enhancement of their attributes to tackle complex diseases, not usually amenable to conventional vaccine strategies.

Citing Articles

Design of Novel Vaccines Based on Virus-Like Particles.

Barcena J, Zamora-Ceballos M, Blanco E Subcell Biochem. 2024; 105:785-821.

PMID: 39738963 DOI: 10.1007/978-3-031-65187-8_21.

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.

Li H, Gong Y, Yan P, Xu Y, Qin G, Wen W Front Immunol. 2024; 15:1453753.

PMID: 39676875 PMC: 11638222. DOI: 10.3389/fimmu.2024.1453753.

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development.

Krenger P, Roques M, Vogt A, Pardini A, Rothen D, Balke I NPJ Vaccines. 2024; 9(1):225.

PMID: 39557901 PMC: 11574195. DOI: 10.1038/s41541-024-01006-8.

Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles.

Neilsen G, Mathew A, Castro J, McFadden W, Wen X, Ong Y mBio. 2024; 15(12):e0336823.

PMID: 39530689 PMC: 11633226. DOI: 10.1128/mbio.03368-23.

A Self-Amplifying Human Papillomavirus 16 Vaccine Candidate Delivered by Tobacco Mosaic Virus-Like Particles.

Karan S, de Oliveira J, Moreno-Gonzalez M, Steinmetz N ACS Appl Bio Mater. 2024; 7(11):7675-7683.

PMID: 39512153 PMC: 11648571. DOI: 10.1021/acsabm.4c01239.

References

Smith M, Lindbo J, Dillard-Telm S, Brosio P, Lasnik A, McCormick A . Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 2006; 348(2):475-88. DOI: 10.1016/j.virol.2005.12.039. View

Low J, Lee L, Ooi E, Ethirajulu K, Yeo P, Matter A . Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014; 32(39):5041-8. DOI: 10.1016/j.vaccine.2014.07.011. View

Haramati N, Lorans R, Lutwin M, Kaleya R . Injection granulomas. Intramuscle or intrafat?. Arch Fam Med. 1994; 3(2):146-8. DOI: 10.1001/archfami.3.2.146. View

Bachmann M, Jennings G . Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010; 10(11):787-96. DOI: 10.1038/nri2868. View

Skibinski D, Jones L, Zhu Y, Xue L, Au B, Lee B . Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine. Sci Rep. 2018; 8(1):18007. PMC: 6301966. DOI: 10.1038/s41598-018-36703-7. View

Bessa J, Jegerlehner A, Hinton H, Pumpens P, Saudan P, Schneider P . Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol. 2009; 183(6):3788-99. DOI: 10.4049/jimmunol.0804004. View

Mohsen M, Gomes A, Cabral-Miranda G, Krueger C, Leoratti F, Stein J . Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. 2017; 251:92-100. DOI: 10.1016/j.jconrel.2017.02.031. View

Storni T, Ruedl C, Schwarz K, Schwendener R, Renner W, Bachmann M . Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004; 172(3):1777-85. DOI: 10.4049/jimmunol.172.3.1777. View

Pastori C, Tudor D, Diomede L, Drillet A, Jegerlehner A, Rohn T . Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology. 2012; 431(1-2):1-11. DOI: 10.1016/j.virol.2012.05.005. View

10.

Tytgat H, Lin C, Levasseur M, Tomek M, Rutschmann C, Mock J . Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies. Nat Commun. 2019; 10(1):5403. PMC: 6881330. DOI: 10.1038/s41467-019-13283-2. View

11.

Krueger C, Thoms F, Keller E, Vogel M, Bachmann M . Virus-Specific Secondary Plasma Cells Produce Elevated Levels of High-Avidity Antibodies but Are Functionally Short Lived. Front Immunol. 2019; 10:1831. PMC: 6691049. DOI: 10.3389/fimmu.2019.01831. View

12.

Bessa J, Kopf M, Bachmann M . Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol. 2010; 184(9):4615-9. DOI: 10.4049/jimmunol.0903949. View

13.

Lee Y, Ko E, Lee Y, Kim K, Kim M, Lee Y . Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. PLoS One. 2018; 13(1):e0190868. PMC: 5764335. DOI: 10.1371/journal.pone.0190868. View

14.

Poland G, Borrud A, Jacobson R, McDermott K, Wollan P, Brakke D . Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA. 1997; 277(21):1709-11. View

15.

Zuckerman J . The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ. 2000; 321(7271):1237-8. PMC: 1118997. DOI: 10.1136/bmj.321.7271.1237. View

16.

Cabral-Miranda G, Lim S, Mohsen M, Pobelov I, Roesti E, Heath M . -Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Infection. Vaccines (Basel). 2019; 7(3). PMC: 6789886. DOI: 10.3390/vaccines7030072. View

17.

Gilfillan C, Wang C, Mohsen M, Rufer N, Hebeisen M, Allard M . Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. Eur J Immunol. 2019; 50(4):505-514. PMC: 7187562. DOI: 10.1002/eji.201948355. View

18.

Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann M . Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2003; 32(11):3305-14. DOI: 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J. View

19.

Stannard L, Hodgkiss M . Morphological irregularities in Dane particle cores. J Gen Virol. 1979; 45(2):509-14. DOI: 10.1099/0022-1317-45-2-509. View

20.

Schwarz K, Meijerink E, Speiser D, Tissot A, Cielens I, Renhof R . Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol. 2005; 35(3):816-21. DOI: 10.1002/eji.200425755. View